Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Launched by LOHMANN & RAUSCHER · Dec 2, 2022
Trial Information
Current as of September 18, 2025
Completed
Keywords
ClinConnect Summary
This clinical investigation will be conducted as 3 weeks, multicentre, open, single-arm cohort study on patients presenting wounds at risk of infection or infected wounds. All wounds of the included patients will be treated with Suprasorb® A +Ag Antimicrobial Calcium Alginate Wound Dressings (and Suprasorb® A + Ag Antimicrobial Calcium Packing Rope - if required by the depth of the wound).
At inclusion visit (V1, day 0), interim visit (V2, after 10 days ±3 days) and termination visit (V3 after 21 days ±3 days or earlier; as soon as the wound is epithelialized completely) patients will have...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Patient is legally capable
- • Presence of a heavily exuding wound
- * Presence of one of the following wounds:
- • pressure ulcers
- • arterial ulcers
- • venous lower leg ulcers
- • diabetic ulcers OR
- • postoperative wound
- • skin graft and donor sites
- • Infected wound (TILI Score ≥ 5) or a wound with risk of infection (W.A.R. Score ≥ 3)
- • Wound area between 4 and 100 cm2
- • It must be possible to display the entire wound area on one photo from a distance of 25-30 cm
- • Patient has signed a written Informed Consent
- Exclusion Criteria:
- • Treatment with Suprasorb® A + Ag Antimicrobial Calcium Algi-nate Wound Dressing and Rope or any silver containing dressing or topical drug during the last 3 weeks
- • Known sensitivity to Suprasorb® A + Ag Antimicrobial Calcium Alginate Wound Dressing and Rope or any of their components
- • Malignant wounds (tumor related wounds)
- • Critical limb ischemia
- • Infected wounds requiring systemic antibiotic therapy at baseline visit or infected wounds with surrounding skin requiring local an-tibiotics at baseline visit and/or during study conduct.
- • Severe sensitive neuropathy (9-10 points on the Neuropathie-Symptom-Score (Diagnose und Therapie der sensomotorischen diabetischen Neuropathien. Diabetes und Stoffwechsel, 11, Suppl.2 (2002))
- • Planned amputation within the next 1 months
- • A planned surgical operation in the region of the study wound within the next 4 weeks following inclusion
- • Patient is not compliant regarding treatment of the underlying disease (e.g. compression)
- • Dry wound
- • Pregnancy or breast feeding
- • Reliable severe malnutrition
- • Patient is analphabet
- • Participation in any clinical trial within the last 1 month and during participation in this study
- • Legal incapacity
About Lohmann & Rauscher
Lohmann & Rauscher is a leading global provider of innovative medical and hygiene products, specializing in wound care, compression therapy, and surgical solutions. With a commitment to enhancing patient outcomes through advanced research and development, the company focuses on delivering high-quality, effective products that meet the evolving needs of healthcare professionals and patients alike. Established with a strong emphasis on sustainability and safety, Lohmann & Rauscher actively engages in clinical trials to advance medical knowledge and improve therapeutic options, ensuring its solutions are backed by robust scientific evidence and real-world efficacy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bolesławiec, Poland
Kraków, Poland
Ostróda, Poland
Oświęcim, Poland
Pabianice, Poland
Wrocław, Poland
łódź,, Poland
świdnica, Poland
Patients applied
Trial Officials
Claudia Feldkamp, Dr.
Study Director
Lohmann & Rauscher
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials